文献速递慢阻肺

氟替卡松糠酸酯与维兰特罗对中度慢阻肺伴心血管风险患者肺功能下降的影响

Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk.
PubMed 文献 · Am J Respir Crit Care Med · 2018-01-01

SUMMIT试验预设分析纳入16,485例中度慢阻肺伴心血管风险患者,比较氟替卡松糠酸酯(FF)、维兰特罗(VI)及联合(FF/VI)与安慰剂对FEV1下降速率的影响。结果显示含FF方案较安慰剂下降更慢(P<0.03),FF/VI较VI单药更慢(P<0.005)。

要点

  • 含FF方案较安慰剂减缓FEV1年下降速率(P<0.03)。
  • FF/VI联合较VI单药进一步减缓FEV1下降(P<0.005)。
  • 当前吸烟、低BMI、男性及合并心血管疾病者FEV1下降更快。

核心结论

  • 在中度慢阻肺伴心血管风险患者中,FF单用或联合VI似乎可减缓FEV1下降速率。

研究设计与样本

  • 事件驱动、随机、安慰剂对照试验(SUMMIT)的预设关键次要结局分析。
  • 纳入16,485例中度慢阻肺伴心血管风险患者,其中15,457例至少一次治疗中肺功能测量用于分析。
  • 每12周测量肺功能,平均每人约7次肺功能评估。
  • 所有统计比较视为名义性。

主要发现

  • 调整后FEV1下降速率:安慰剂-46 ml/年(基线-3.0%),VI -47 ml/年(-3.1%),FF -38 ml/年(-2.5%),FF/VI -38 ml/年(-2.3%)。
  • 含FF方案较安慰剂下降速率更低(P<0.03)。
  • FF/VI较VI单药下降速率更低(P<0.005)。
  • 当前吸烟者、低体重指数者、男性及已患心血管疾病者FEV1下降更快。

临床怎么用

  • 对中度慢阻肺伴心血管风险患者,含FF方案可能有助于减缓肺功能下降。
  • 当前吸烟、低BMI、男性及合并心血管疾病者肺功能下降更快,需关注。

局限性

  • 所有统计比较视为名义性。
  • 分析基于至少一次治疗中肺功能测量的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Many patients with chronic obstructive pulmonary disease (COPD) have an accelerated loss of lung function. It is unclear whether drug treatment can modify this in patients with moderately severe disease. OBJECTIVES: In a prespecified analysis of the key secondary outcome in SUMMIT (Study to Understand Mortality and Morbidity), we investigated whether the inhaled corticosteroid fluticasone furoate (FF; 100 μg), the long-acting β-agonist vilanterol (VI; 25 μg), or their combination (FF/VI) modified the rate of decline in FEV1 compared with placebo. We also investigated how baseline covariates affected this decline. METHODS: Spirometry was measured every 12 weeks in this event-driven, randomized, placebo-controlled trial of 16,485 patients with moderate COPD and heightened cardiovascular risk. An average of seven spirometric assessments per subject among the 15,457 patients with at least one on-treatment measurement were used in the analysis of rate of FEV1 decline. All statistical comparisons are considered nominal. MEASUREMENTS AND MAIN RESULTS: The adjusted rates of FEV1 decline were -46 ml/yr (-3.0% of baseline) with placebo, -47 ml/yr (-3.1%) with VI, -38 ml/yr (-2.5%) with FF, and -38 ml/yr (-2.3%) with FF/VI. FF-containing regimens had lower rates of decline than placebo (P < 0.03), and FF/VI had a lower rate of decline than VI alone (P < 0.005). The FEV1 decline was faster in current smokers, those with a lower body mass index, males, and patients with established cardiovascular disease. CONCLUSIONS: In patients with moderate COPD and heightened cardiovascular risk, FF alone or in combination with VI appears to reduce the rate of FEV1 decline. Clinical trial registered with www.clinicaltrials.gov (NCT01313676).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Calverley PMA, Anderson JA, Brook RD, et al. Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. Am J Respir Crit Care Med. 2018. PMID: 28737971. doi:10.1164/rccm.201610-2086OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。